Cross activation of EGFR downstream pathways by the hepatocyte growth factor receptor (c-MET) mediates resistance to EGFR-TKIs and anti-EGFR antibodies in NSCLC and CRC models [28, 29]. The gene discussed is MET; the disease is colorectal carcinoma.